GlassScriptPhysician profile
Joseph Obi
NPI 1497117253
$2,999.37
in general payments reported to CMS, 2019-2025
24 companies · $839 in 2025
The $839 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $97.04 · 2022: $328 · 2023: $750 · 2024: $986 · 2025: $839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,564 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,564.15 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $917.43 | 2022-2025 | |
| Qol Medical, LLC | $315.42 | 2022-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $273.23 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $219.84 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Aimmune Therapeutics, INC. | $176.82 | 2024-2025 | Vowst, Zenpep |
| Ardelyx, INC. | $145.54 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.65 | 2022-2024 | Xifaxan, Trulance |
| Genzyme Corporation | $107.01 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.34 | 2022-2025 | Gattex, Entyvio |
| Boston Scientific Corporation | $97.04 | 2021 | |
| Mauna Kea Technologies, INC. | $91.41 | 2023-2025 | |
| Erbe USA INC | $75.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $74.82 | 2022-2025 | Dupixent |
| Celgene Corporation | $59.25 | 2023-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $50.47 | 2024-2025 | Iqirvo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $33.40 | 2023-2025 | Ocaliva |
| Celltrion USA INC. | $22.16 | 2024 | Vegzelma |
| Merck Sharp & Dohme LLC | $21.23 | 2024 | Dificid |
| E.R. Squibb & Sons, L.L.C. | $19.53 | 2024 | Zeposia |
| Amgen INC. | $19.51 | 2023 | Avsola |
| Phathom Pharmaceuticals, INC. | $18.42 | 2025 | Voquezna |
| Lilly USA, LLC | $17.63 | 2023 | |
| Nestle Healthcare Nutrition INC. | $12.74 | 2023 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Obi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.